FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W17962661> ?p ?o ?g. }

• W17962661 abstract "Abstract Background The value of Allo-SCT in myeloma is heavily disputed. In our previous Donor versus No Donor (DvND) comparison we found no survival benefit of Allo-RIC in newly diagnosed myeloma. (Lokhorst et al:Blood 2012119: 6219-6225). However, a recent update of the EBMT-NMA 2000 trial (Gahrton el al:Blood 2013121: 5055-506) suggested that extended follow-up (> 5 years) may be necessary for a correct interpretation of a potential survival benefit for Allo-RIC. Here we present the extended follow-up of our trial, in which the median follow-up of patients now exceeds over 7.5 years since the first autologous SCT. Methods Patients with an HLA–identical sibling donor included in the phase III HOVON-50 study, that was designed to assess the role of thalidomide in induction treatment and maintenance after high-dose therapy (HDM 200 mg/m2), could proceed to the Hovon 54 study in which an Allo-SCT was performed after conditioning with low dose TBI only, between 2-6 months after HDM. Among the 536 eligible patients randomized in the HOVON-50 trial, ultimately 260 patients were eligible to be included into the DvND analysis: 122 patients with a donor, of whom 99 patients received an Allo-RIC and 138 without a donor, of whom 115 patients started maintenance therapy with thalidomide. Groups were comparable with regard to age, myeloma stage, and prognostic factors including cytogenetics and ISS stage. Results 93% of the patients in the no donor group achieved at least a PR (38% CR, 71% at least VGPR ), versus 96% of the patients in the donor group (43% CR, 73% at least VGPR). After a median follow-up of 91 months after HDM, PFS and OS were comparable between the two groups. In the intention to treat analysis median PFS was 29 months for the no donor group and 30 months the no donor group (P=0.25). Median OS was 76 for the donor group and 81 months for the no donor group (P=0.61). For the patients who actually received their allocated treatment (Allo-RIC or maintenance), PFS curves started to diverge after 3 years, however no statistical difference was observed (P=0.07). Allo-RIC improved the median overall survival from 73 to 94 months compared to patients receiving maintenance. However, due to frequent late mortality (> after 96 months) in the Allo-RIC group the benefit was not statistically significant (P=0.54). No subgroup including those achieving CR or those with high risk features (ISS, deletion of chromosome 13) did benefit from Allo-RIC. Conclusion This analysis failed to show improvement of tandem Auto Allo-RIC as part of first line therapy in myeloma as compared to Auto-SCT followed by maintenance therapy, even after extended follow-up. Disclosures: Lokhorst: Genmab A/S: Consultancy, Research Funding; Celgene: Honoraria; Johnson-Cilag: Honoraria; Mudipharma: Honoraria. Minnema:Janssen Cilag: Consultancy, Honoraria. Sonneveld:Janssen-Cilag: Honoraria; Celgene: Honoraria; Onyx: Honoraria; Janssen-Cilag: Research Funding; Millenium: Research Funding; Onyx: Research Funding; Celgene: Research Funding." @default.
• W17962661 created "2016-06-24" @default.
• W17962661 creator A5002972322 @default.
• W17962661 creator A5008906420 @default.
• W17962661 creator A5009079290 @default.
• W17962661 creator A5012101669 @default.
• W17962661 creator A5020528788 @default.
• W17962661 creator A5023165076 @default.
• W17962661 creator A5036293139 @default.
• W17962661 creator A5042286198 @default.
• W17962661 creator A5049251029 @default.
• W17962661 creator A5049413660 @default.
• W17962661 creator A5058429057 @default.
• W17962661 creator A5066560929 @default.
• W17962661 creator A5073604089 @default.
• W17962661 creator A5082157943 @default.
• W17962661 creator A5083385949 @default.
• W17962661 creator A5083928280 @default.
• W17962661 date "2013-11-15" @default.
• W17962661 modified "2023-09-28" @default.
• W17962661 title "No Improvement Of Overall Survival After Extended Follow-Up Of Donor Versus No Donor Analysis Of Newly Diagnosed Myeloma Patients Included In The HOVON 50/54 Study" @default.
• W17962661 doi "https://doi.org/10.1182/blood.v122.21.2132.2132" @default.
• W17962661 hasPublicationYear "2013" @default.
• W17962661 type Work @default.
• W17962661 sameAs 17962661 @default.
• W17962661 citedByCount "0" @default.
• W17962661 crossrefType "journal-article" @default.
• W17962661 hasAuthorship W17962661A5002972322 @default.
• W17962661 hasAuthorship W17962661A5008906420 @default.
• W17962661 hasAuthorship W17962661A5009079290 @default.
• W17962661 hasAuthorship W17962661A5012101669 @default.
• W17962661 hasAuthorship W17962661A5020528788 @default.
• W17962661 hasAuthorship W17962661A5023165076 @default.
• W17962661 hasAuthorship W17962661A5036293139 @default.
• W17962661 hasAuthorship W17962661A5042286198 @default.
• W17962661 hasAuthorship W17962661A5049251029 @default.
• W17962661 hasAuthorship W17962661A5049413660 @default.
• W17962661 hasAuthorship W17962661A5058429057 @default.
• W17962661 hasAuthorship W17962661A5066560929 @default.
• W17962661 hasAuthorship W17962661A5073604089 @default.
• W17962661 hasAuthorship W17962661A5082157943 @default.
• W17962661 hasAuthorship W17962661A5083385949 @default.
• W17962661 hasAuthorship W17962661A5083928280 @default.
• W17962661 hasConcept C126322002 @default.
• W17962661 hasConcept C141071460 @default.
• W17962661 hasConcept C2776364478 @default.
• W17962661 hasConcept C2779609412 @default.
• W17962661 hasConcept C71924100 @default.
• W17962661 hasConceptScore W17962661C126322002 @default.
• W17962661 hasConceptScore W17962661C141071460 @default.
• W17962661 hasConceptScore W17962661C2776364478 @default.
• W17962661 hasConceptScore W17962661C2779609412 @default.
• W17962661 hasConceptScore W17962661C71924100 @default.
• W17962661 hasLocation W179626611 @default.
• W17962661 hasOpenAccess W17962661 @default.
• W17962661 hasPrimaryLocation W179626611 @default.
• W17962661 hasRelatedWork W1496735223 @default.
• W17962661 hasRelatedWork W1828155201 @default.
• W17962661 hasRelatedWork W2248002030 @default.
• W17962661 hasRelatedWork W2468483596 @default.
• W17962661 hasRelatedWork W2470026352 @default.
• W17962661 hasRelatedWork W2521916454 @default.
• W17962661 hasRelatedWork W2538114067 @default.
• W17962661 hasRelatedWork W2547069390 @default.
• W17962661 hasRelatedWork W2555945168 @default.
• W17962661 hasRelatedWork W2559280771 @default.
• W17962661 hasRelatedWork W2576981172 @default.
• W17962661 hasRelatedWork W2577394395 @default.
• W17962661 hasRelatedWork W2580547579 @default.
• W17962661 hasRelatedWork W2600140196 @default.
• W17962661 hasRelatedWork W2725206342 @default.
• W17962661 hasRelatedWork W2757936111 @default.
• W17962661 hasRelatedWork W2775468048 @default.
• W17962661 hasRelatedWork W2980062560 @default.
• W17962661 hasRelatedWork W2980625790 @default.
• W17962661 hasRelatedWork W2993778492 @default.
• W17962661 isParatext "false" @default.
• W17962661 isRetracted "false" @default.
• W17962661 magId "17962661" @default.
• W17962661 workType "article" @default.